Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension and safety monitoring study of etrolizumab in moderate to severe ulcerative colitis
MOH_2017-07-20_000658Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Etrolizumab in autoimmune colitis (2 arms), sponsored by Roche. Primary endpoints: Long-term safety and PML symptom monitoring. Started Nov 2014; status: completed.
02
Drugs
Etrolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-07-20_000658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-20_000658.